ANZCTR search results

There is currently no non invasive way to diagnose endometriosis. The gold standard is laparoscopy plus directed biopsy. Previous studies have suggested that endometrial nerve fibre detection may function as a less invasive outpatient test of endometriosis. This work suggested that if fine nerve fibres (C type unmyelinated) are present in the functional layer of the endometrium then the patient has endometriosis and if the fibres are not present the patient does not have endometriosis. We wish to recruit women with pelvic pain as we wonder if the nerve fibres relate to the painful condition rather than to endometriosis. We will perform endometrial nerve fibre detection in 20 women with pain and no endometriosis and 20 women with pain who have endometriosis. Our hypothesis is that fine nerve fibres will be found in the functional layer of the endometrium in women both with and without endometriosis who also have pelvic pain. Thus endometrial nerve fibre detection is not a useful way to diagnose endometriosis.

The purpose of this study is to see if a combination of weight loss and low salt diets have a beneficial effect on how blood vessels work. We hypothesise that decreasing salt in the diet and losing weight will improve blood vessel function.

The primary purpose of this study on healthy volunteers is to determine the safety and tolerability of AD-6626 without and without alcohol administration in normal healthy volunteers and subjects heterozygous (HeZ) for the aldehyde dehydrogenase 2 (ALDH2)*1/*2 genetic variant

The National Trauma Research Institute (NTRI) has delivered the Prevent Alcohol & Risk-related Trauma in Youth program or P.A.R.T.Y. at The Alfred in Melbourne since 2009. P.A.R.T.Y. is a trauma prevention and health promotion initiative that seeks to build resilience in participants through the lived experience of a major trauma service, aiming to effect a change in the perception that traumatic injury will not happen to them. Through presentations from health professionals, encounters with trauma patients, tours through the critical care areas of the hospital, and hands on rehabilitation activities, P.A.R.T.Y. participants get to experience what trauma really feels like first hand. The NTRI’s P.A.R.T.Y. Defence program for trainees has been operating at The Alfred since 2011. A retrospective pilot evaluation is underway suggesting a benefit in those “at-risk” trainees who attended the in-hospital P.A.R.T.Y program. Repeat alcohol-related incidents in the program group are low. However, in the absence of verified, published data on the numbers of alcohol-related incidents in at-risk trainees, a more robust research project that uses a validated screening tool and control groups is needed. This proposed research program involves a randomized controlled trial; focused on new trainees. All participate trainees will complete the validated, World Health Organization’s Alcohol Use Disorders Identification Test (AUDIT), which is a screening tool for alcohol-related behavior already used by the RAN in those deemed “at risk”. Participants will be randomly allocated to attend P.A.R.T.Y. Defence (either at the hospital or on-base at CERBERUS) or to not participate in P.A.R.T.Y. at all. All participants will be followed up at 12 months to repeat the AUDIT and other measures in order to measure the effectiveness of P.A.R.T.Y. in reducing alcohol-related harms.

Applying a mild electrical current to the head is known to improve brain functions related to attention and learning without causing significant adverse side effects other than a mild local skin irritation at the stimulation site. The current study investigates stimulation effects whilst children - diagnosed with mild to moderate attention deficit hyperactivity disorder - undergo their regular occupational therapy.

Information from continuous glucose sensors is complicated. Insulin pumps can be set in many ways and the settings are complicated and may vary depending of the person making the changes. This study compares the results after insulin pumps are adjusted by a doctor or by a computer program.

Children admitted to a paediatric intensive care unit (PICU) frequently require the insertion of a CVAD for the administration of medication and fluids. These CVADs are associated with a high rate of failure, including CVAD-related bloodstream infection (BSI). In order to prevent failure, dressings, such as bordered polyurethane (BPU), are used to protect the CVAD insertion site from contamination. Additional securement devices, such as sutures, are used to reduce movement of the catheter. New products, including tissue adhesive (TA), sutureless securement devices (SSD), and combined securement and dressing products (CSD), are available to clinicians to provide securement and dressings for CVAD. It is not known whether these new products are effective at reducing CVAD failure, in comparison to standard care (BPU and suture). The primary aim of this research is to evaluate the feasibility of launching a full-scale efficacy trial, using pre-defined feasibility criteria for recruitment, retention and protocol fidelity. The secondary aim is to compare the effectiveness of dressings and securement products on CVAD failure due to infection, occlusion, dislodgement, thrombosis, or breakage, for children with percuteanous CVAD in the PICU.

This study will determine whether selinexor has any effects against Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T cell Lymphoma (CTCL). Who is it for? You may be eligible to join this study if you are aged 18 years or above and Relapsed or Refractory PTCL or CTCL Study details This study drug, selinexor, works by trapping “tumour suppressing proteins” within the cell and thus causing the cancer cells to die or stop growing. Selinexor has previously been tested in humans to define a safe dose to be administered. It is not known at this time if selinexor will treat PTCL/CTCL. This study will examine the effects of selinexor on PTCL/CTCL and look at the side-effects. After signing the consent, participants will undergo screening assessments up to 30 days before the first dosing. These include: medical and medication history taking, eye examination, ECG, Echocardiogram or MUGA scan, chest X-ray, CT/MRI scans, tumour or skin biopsy, bone marrow aspirate or biopsy, height, weight, vital signs measurement, physical exam, and urine and safety blood tests. Eligible participants will receive oral selinexor tablets on Days 1 and 3 of Weeks 1-3 of each 4-week (28 day) cycle (6 doses/cycle) until disease progression or intolerability. The dose of selinexor will be either 100mg or 80 mg depending on the participants’ body surface area (calculated from their height and weight). Participants will also take dexamethasone to improve selinexor tolerability and antinausea drugs (e.g. ondansetron) to minimise nausea. Additional anti-nausea and anti-anorexia agents may be given as needed. The assessments done at screening will be repeated at various intervals to monitor safety and assess efficacy of the selinexor. In addition, photographs of skin lesions (CTCL patients only) will be taken and blood samples will be taken to check the level of selinexor in the blood at certain timepoints, and to test the binding of selinexor in the blood. Follow-up visits will occur 30 and 60 days after the last dose of selinexor, then participants will be contacted every 3 months to check on their disease status and other treatments.

Children admitted to an acute care facility frequently require the insertion of a peripherally inserted central catheter (PICC) for the administration of medication and fluids. These PICCs are associated with a high rate of failure, including PICC-related bloodstream infection (BSI). In order to prevent failure, dressings, such as bordered polyurethane (BPU) and sutureless securement devices (SSD), are used to protect the PICC insertion site from contamination. Additional securement devices, such as sutures, are used to reduce movement of the catheter. New products, including tissue adhesive (TA), and combined securement and dressing products (CSD), are available to clinicians to provide securement and dressings for PICC. It is not known whether these new products are effective at reducing PICC failure and complication, in comparison to standard care (BPU and SSD). The primary aim of this research is to evaluate the feasibility of launching a full-scale efficacy trial, using pre-defined feasibility criteria for recruitment, retention and protocol fidelity. The secondary aim is to compare the effectiveness of dressings and securement products on PICC failure and complication due to infection, occlusion, dislodgement, thrombosis, or breakage, for children with PICC in acute care.

This is the first in human study with PXS-4728A. The primary aim of the study is to establish the safety and tolerability while the secondary aim is to understand the pharmacokinetics and pharmacodynamics of PXS-4728A in healthy males.